Proesmans M, Heyns Lieve, Moons Philip, Havermans Trudy, De Boeck Kris
Department of Pediatrics, Pediatric Pulmonology, Cystic Fibrosis Centre, University Hospital of Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Respir Med. 2009 Feb;103(2):244-50. doi: 10.1016/j.rmed.2008.08.017. Epub 2008 Oct 9.
Limited data exist on the efficacy and safety of home intravenous antibiotic (IV-AB) therapy for pulmonary infection specifically in children with cystic fibrosis (CF).
We report on the outcome of IV-AB in the home vs hospital setting based on retrospective single centre patient data from 1999 to 2004 (age >5 and <18 years). Treatment location was chosen based on estimation of competence, adherence, social background and patient preference. Primary outcome parameter was change in FEV(1). Secondary outcome parameters were weight and IgG as well as occurrence of complications.
One hundred and thirty-one treatment observations (TOs) were analysed for 47 patients. Mean age was 13.32 (+/-2.9) years and mean FEV(1) 65 (+/-19) % predicted. Fifty-four (41%) TO's were home and 77 (59%) were hospital treatments. Percent change in FEV(1) and weight gain was comparable in the 2 settings. Complications were rare in both groups.
The outcome of IV-AB therapy for lung infection in children with CF was not inferior in the home compared to the hospital setting. In our centre, home IV-AB treatment is a valuable treatment option for children with CF.
关于家庭静脉用抗生素（IV-AB）治疗肺部感染，尤其是囊性纤维化（CF）患儿的疗效和安全性的数据有限。
我们基于1999年至2004年（年龄>5岁且<18岁）单中心回顾性患者数据，报告家庭与医院环境下IV-AB治疗的结果。根据能力评估、依从性、社会背景和患者偏好选择治疗地点。主要结局参数是第一秒用力呼气容积（FEV₁）的变化。次要结局参数是体重、免疫球蛋白G（IgG）以及并发症的发生情况。
对47例患者的131次治疗观察（TOs）进行了分析。平均年龄为13.32（±2.9）岁，平均FEV₁为预测值的65（±19）%。54次（41%）TOs为家庭治疗，77次（59%）为医院治疗。两种环境下FEV₁的百分比变化和体重增加相当。两组并发症均少见。
CF患儿肺部感染的IV-AB治疗结果在家庭环境中并不比医院环境差。在我们中心，家庭IV-AB治疗是CF患儿的一种有价值的治疗选择。
